- Home
- AGO vs DNLI Comparison
AGO vs DNLI Comparison
Compare AGO & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGO | DNLI |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.0B |
| IPO Year | 2003 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AGO | DNLI |
|---|---|---|
| Price | $77.29 | $18.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $101.67 | $34.33 |
| AVG Volume (30 Days) | 414.6K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | ★ 49.34 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $1,110,000,000.00 | N/A |
| Revenue This Year | $3.06 | N/A |
| Revenue Next Year | N/A | $408.85 |
| P/E Ratio | $41.12 | ★ N/A |
| Revenue Growth | ★ 27.29 | N/A |
| 52 Week Low | $74.18 | $12.58 |
| 52 Week High | $92.40 | $23.77 |
Technical Indicators
Market Signals| Indicator | AGO | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 46.17 |
| Support Level | $74.18 | $18.86 |
| Resistance Level | $84.42 | $20.40 |
| Average True Range (ATR) | 1.92 | 1.01 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 32.29 | 40.85 |
Price Performance
Historical ComparisonAbout AGO Assured Guaranty Ltd.
Assured Guaranty Ltd. provides credit protection products to the United States and international public finance and structured finance markets and manages assets across collateralized loan obligations as well as opportunity funds and liquid funds that build on its corporate credit, asset-based finance, municipal, and healthcare experience. The company operates in two segments: the Insurance segment and the Asset Management segment. The majority of the revenue earned by the company is from the Insurance segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.